Mr. Andrew Newell, Non Executive Chairman
Andrew is the Managing Director of Exomedica Ltd, the medical technology development company. He has worked in the investment industry and venture capital for 25 years as a specialist in intellectual property and copyrights within the brands and media industries, and now in medical technology. Most recently he was Investment Director for Proven Private Equity and a partner of Media Ventures Partners, both leading media investors with demonstrable success in delivering value to shareholders. A graduate of Magdalen College, Oxford and the London Business School, Andrew has previously worked in investment for Oppenheimer, Enskilda Securities and Fidelity International.
Mr. Sameer Kothari, Chief Executive Director
Sameer brings over 15 years commercial experience to Zilico. Prior to joining in November 2007 Sameer was CEO of Plasso Technology Ltd, a venture capital-backed company developing research tools and labware for the life sciences. 2007 saw the launch of its first product, EpranEx, a new generation research tool for life scientists. In May 2007, Sameer successfully led a trade sale exit of Plasso to Becton Dickinson Inc.. Prior to joining Plasso, Sameer was a senior executive, with roles in strategy, business development, HR and M&A within Marconi plc. Including a management board position within mainland Europe.
Mr. Steven Couldwell, Non Executive Director
With over 14 years of senior management experience, Steven Couldwell is currently Chief Operating Officer and Head of Global Biosurgery, a division of Sanofi Corporation. He has a proven international track record in driving revenues and profit growth in both the medical device and CRO industries. Steven was formerly Vice President and General Manager of Covalence Laboratories Europe and worked for Smith & Nephew for almost 20 years in a number of roles including President orthopaedics (Europe) and Senior VP Sales and Marketing for Smith & Nephew¹s Advanced Wound Management business
Dr. Alan Folwell, Non Executive Director
Alan has exceptional business experience following a range of senior roles in manufacturing and technology-based industries. His leadership experience encompasses a range of sectors from aerospace to carpets, and has always had a major international content. Alan's particular interests are in fostering, growing and developing technology- and knowledge-based activities. Alan was also the first chief executive of the Central Technology Belt, to which he now acts as special adviser. A chartered engineer by training, he also has a degree and doctorate from Cambridge University where he was also a double rugby Blue.
Dr. Jonathan Gee, Non Executive Director
Jonathan is responsible for SPARK's healthcare and life science investment activities. He has over fifteen years experience working with IP driven high growth technology companies as an investor and board member and as Chief Executive of technology exploitation companies. His investment focus covers all healthcare from drug discovery to devices and diagnostics. Investments he has led include Oxford Immunotec, which floated on NASDAQ in November, 2013 and GlycArt Biotechnology, acquired by Roche for over £100m in July, 2005.